Agenus' bot/bal data in pretreated liver cancer presented at aacr 2025

Lexington, mass.--(business wire)--agenus inc. (nasdaq: agen), a clinical-stage immuno-oncology company, today announced updated data from the hepatocellular carcinoma (hcc) cohort of its ongoing phase 1 study evaluating botensilimab (bot) in combination with balstilimab (bal). these findings are being presented at the american association for cancer research (aacr) annual meeting in chicago, illinois. the hcc cohort comprised patients with difficult-to-treat disease who had progressed followin.
AGEN Ratings Summary
AGEN Quant Ranking